The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma.

No abstract is available for this paper.

• Publication year

  1994

• Venue

  American Journal of Obstetrics and Gynecology

• Publication date

  1994-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0002-9378(94)70090-7PMID 8166218
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cancer statistics, 1993

  1993cited by this paper
• The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study.

  1992cited by this paper
• Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience.

  1991cited by this paper
• Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study.

  1989cited by this paper
• Therapy of stage III (optimal) epithelial carcinoma of the ovary with melphalan or melphalan plus Corynebacterium parvum (a Gynecologic Oncology Group Study).

  1987cited by this paper
• A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer.

  1986cited by this paper
• A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A gynecologic oncology group study

  1986cited by this paper
• Therapy of stage III (optimal) epithelial carcinoma of the ovary with melphalan or melphalan plus corynebacterium parvum (a gynecologic oncology group study)

  1986cited by this paper
• Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma.

  1984cited by this paper
• Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy.

  1978cited by this paper
• Granulocyte transfusions for infection during neutropenia.

  1975cited by this paper
• Diagnosis and staging of ovarian carcinoma.

  1975cited by this paper
• Diagnosis and staging of ovarian carcinoma.

  1975cited by this paper
• Letter: Fenfluramine and dreaming.

  1974cited by this paper

• Is omentectomy mandatory in patients with epithelial ovarian cancer having a macroscopically normal-appearing omentum?: A retrospective study

  2026cites this paper
• Highlights from the third Colombian conference on women's cancers.

  2025cites this paper
• Proposed Nodal Cancer Index (NCI) in ovarian carcinomatosis

  2025cites this paper
• Survival of patients with 2014 FIGO stage IIIC high-grade serous ovarian cancer who were treated with platin-based adjuvant chemotherapy

  2025cites this paper
• Surgery in Ovarian Cancer—Brazilian Society of Surgical Oncology Consensus

  2025cites this paper
• Surgery for Recurrent Ovarian Cancer.

  2025cites this paper
• An Assessment of the Effectiveness of Preoperative İmaging Modalities (MRI, CT, and 18F-FDG PET/CT) in Determining the Extent of Disease Spread in Epithelial Ovarian–Tubal–Peritoneal Cancer (EOC)

  2025cites this paper
• Prognosis and Therapy of Ovarian Cancer, Part 1: Patient Selection and Surgical Management in Advanced Ovarian Cancer – What Tools Do We Have to Make the Right Decision?

  2025cites this paper
• Extra-abdominal cytoreductive techniques in ovarian cancer: how far can (should) we go?

  2024cites this paper
• Evaluation of Circulating Cell-Free DNA Levels in Predicting Operability During Interval Cytoreduction for Advanced Epithelial Ovarian Cancers

  2024cites this paper
• Interactive Electronic Pegboard for Enhancing Manual Dexterity and Cognitive Abilities: Instrument Usability Study

  2024cites this paper
• New Insights into the Assessment of Peri-Operative Risk in Women Undergoing Surgery for Gynecological Neoplasms: A Call for a New Tool

  2024cites this paper
• Symptom-triggered testing detects early stage and low volume resectable advanced stage ovarian cancer

  2024cites this paper
• Survival impact and safety of intrathoracic and abdominopelvic cytoreductive surgery in advanced ovarian cancer: a systematic review and meta-analysis

  2024cites this paper
• Surgery for Recurrent Ovarian Cancer

  2024cites this paper
• Complete Cytoreduction in Advanced Epithelial Ovarian Cancer: The Time Has Come to Define a Standard Boundary

  2023cites this paper
• Impact of obese patients in ovarian cancer surgery on postoperative wound complications: A meta‐analysis

  2023cites this paper
• Diffusion-weighted magnetic resonance imaging for the pre-operative evaluation of epithelial ovarian cancer patients.

  2023cites this paper
• Intrathoracic surgery as part of primary cytoreduction for advanced ovarian cancer: Going to the next level - A Memorial Sloan Kettering Cancer Center study.

  2023cites this paper
• Chemotherapy-Induced Neutropenia as a Prognostic Factor in Patients With Advanced Epithelial Ovarian Carcinoma

  2023cites this paper
• Localized chemotherapy approaches and advanced drug delivery strategies: a step forward in the treatment of peritoneal carcinomatosis from ovarian cancer

  2023cites this paper
• Effect of Hospital Case-Volume on Mortality after Ovarian Cancer Surgery: A Population-Based Retrospective Cohort Study

  2022cites this paper
• Residual Disease Threshold After Primary Surgical Treatment for Advanced Epithelial Ovarian Cancer, Part 1: A Systematic Review and Network Meta-Analysis

  2022cites this paper
• A review of robotic surgery in the management of recurrent ovarian carcinoma: indication and techniques

  2022cites this paper
• Multiple isolated ovarian cancer recurrences in the cervix and vagina after supracervical hysterectomy: A case report

  2022cites this paper
• Surgery in Advanced Ovary Cancer: Primary versus Interval Cytoreduction

  2022cites this paper
• High expression of CETN2 is associated with platinum resistance and poor prognosis in epithelial ovarian cancer

  2022cites this paper
• Intraoperative Tumor Detection Using Pafolacianine

  2022cites this paper
• Investigating the effect of optimal cytoreduction in the context of platinum sensitivity in high‐grade serous ovarian cancer

  2022cites this paper
• Anastomotic Leakage after Colorectal Surgery in Ovarian Cancer: Drainage, Stoma Utility and Risk Factors

  2022cites this paper
• Sequential Targeting of PLK1 and PARP1 Reverses the Resistance to PARP Inhibitors and Enhances Platin-Based Chemotherapy in BRCA-Deficient High-Grade Serous Ovarian Cancer with KRAS Amplification

  2022cites this paper
• Predictors of early mortality risk in patients with epithelial ovarian cancer

  2022cites this paper
• Cytoreductive Surgery (CRS) and HIPEC for Advanced Ovarian Cancer with Peritoneal Metastases: Italian PSM Oncoteam Evidence and Study Purposes

  2022cites this paper
• Neoadjuvant Chemotherapy Versus Primary Debulking Surgery in FIGO Stage III and IV Epithelial Ovarian, Tubal or Peritoneal Cancer: A Systematic Review and Meta-Analysis

  2022cites this paper
• Diagnostic accuracy of 18F-FDG PET/CT scan for peritoneal metastases in advanced ovarian cancer.

  2021cites this paper
• CT-Based Fagotti Scoring System for Non-Invasive Prediction of Cytoreduction Surgery Outcome in Patients with Advanced Ovarian Cancer

  2021cites this paper
• Surgical Gynecologic Oncology

  2021cites this paper
• Modified intestinal isolation bag as promising tool in promoting bowel resumption after ovarian cancer cytoreductive surgery: a randomized clinical trial

  2021cites this paper
• Validation of three predictive models for suboptimal cytoreductive surgery in advanced ovarian cancer

  2021cites this paper
• The Role of CRS and HIPEC in Ovarian Cancer

  2021cites this paper
• The role of multiple bowel resections in advanced ovarian cancer: survival and surgical outcomes—a narrative review

  2021cites this paper
• MicroRNA characteristics in epithelial ovarian cancer

  2021cites this paper
• Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.

  2021cites this paper
• Retroileal colorectal anastomosis after left-sided or transverse colectomy for advanced serous carcinoma of the ovary or uterus

  2021cites this paper
• Predictors of Survival Outcomes After Primary Treatment of Epithelial Ovarian Cancer in Lagos, Nigeria

  2021cites this paper
• Efficacy of neoadjuvant hyperthermic intraperitoneal chemotherapy in advanced high-grade serous ovarian cancer (the NHIPEC trial): study protocol for a randomised controlled trial

  2021cites this paper
• Epithelial Ovarian Cancer and Cancer Stem Cells.

  2021cites this paper
• Retroperitoneal lymph node recurrence of epithelial ovarian cancer: Prognostic factors and treatment outcome.

  2020cites this paper
• Neoadjuvant chemotherapy for IIIC stage ovarian cancer - case report

  2020cites this paper
• Neoadjuvant chemotherapy followed by interval debulking surgery versus primary debulking surgery in the advanced epithelial ovarian cancer- a retrospective cohort study

  2020cites this paper
• Hospital case-volume and mortality after ovarian cancer surgery: a population-based retrospective cohort study

  2020cites this paper
• Tissue-based long non-coding RNAs "PVT1, TUG1 and MEG3" signature predicts Cisplatin resistance in ovarian Cancer.

  2020cites this paper
• Frontline Management of Epithelial Ovarian Cancer—Combining Clinical Expertise with Community Practice Collaboration and Cutting-Edge Research

  2020cites this paper
• Patterns of clinicopathological features and outcome in epithelial ovarian cancer patients: 35 years of prospectively collected data

  2020cites this paper
• Expression of p52, a non-canonical NF-kappaB transcription factor, is associated with poor ovarian cancer prognosis

  2020cites this paper
• Does preoperative CA-125 cutoff value and percent reduction in CA-125 levels correlate with surgical and survival outcome after neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer? – Our experience from a tertiary cancer institute

  2020cites this paper
• Critical Analysis of Stage IV Epithelial Ovarian Cancer Patients after Treatment with Neoadjuvant Chemotherapy followed by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC)

  2020cites this paper
• The Role Of Quaternary Cytoreduction In Relapsed Ovarian Cancer – A Systematic Review

  2020cites this paper
• Feasibility and safety of neoadjuvant laparoscopic hyperthermic intraperitoneal chemotherapy in patients with advanced stage ovarian cancer: a single-center experience

  2019cites this paper
• Outcomes of surgery in epithelial ovarian cancer: our experience

  2019cites this paper
• [Retrospective study: Late surgery post chemotherapy versus after 3-4 cures in treatment of advanced ovarian cancer].

  2019cites this paper
• A three-pronged approach to evaluating robotic surgery

  2019cites this paper
• Honokiol induces apoptosis and suppresses migration and invasion of ovarian carcinoma cells via AMPK/mTOR signaling pathway

  2019cites this paper
• Patient preferences for attributes of primary surgical debulking versus neoadjuvant chemotherapy for treatment of newly diagnosed ovarian cancer

  2019cites this paper
• Quality of Care and Outcomes of Patients With Gynecologic Malignancies Treated at Safety-Net Hospitals

  2019cites this paper
• PET/MR Imaging of the Female Pelvis.

  2019cites this paper
• Chirurgia dei tumori epiteliali maligni dell’ovaio

  2019cites this paper
• PI3K-AKT-mTOR and NFκB Pathways in Ovarian Cancer: Implications for Targeted Therapeutics

  2019cites this paper
• The ability of whole-body SUVmax in F-18 FDG PET/CT to predict suboptimal cytoreduction during primary debulking surgery for advanced ovarian cancer

  2019cites this paper
• Cirugía de tumores epiteliales malignos del ovario

  2019cites this paper
• Pleura and Peritoneum

  2019cites this paper
• The prognostic value of residual disease after neoadjuvant chemotherapy in advanced ovarian cancer; A systematic review.

  2019cites this paper
• Health-related quality of life after interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with stage III ovarian cancer.

  2019cites this paper
• Shaping the standard of care in ovarian cancer management: A review of Gynecologic Oncology Group (GOG)/NRG oncology clinical trials of the past twenty years.

  2019cites this paper
• Cirugía de los tumores epiteliales malignos ováricos

  2019cites this paper
• Upper Abdomen

  2019cites this paper
• Prognostic Significance of Lymph Node Ratio in Ovarian Cancer

  2019cites this paper
• CT prediction of surgical outcome in patients with advanced epithelial ovarian carcinoma undergoing neoadjuvant chemotherapy.

  2019cites this paper
• Top‐cited articles in the Journal: a bibliometric analysis

  2019cites this paper
• No improvement in long-term survival for epithelial ovarian cancer patients: A population-based study between 1989 and 2014 in the Netherlands.

  2018cites this paper
• Concordance of a laparoscopic scoring algorithm with primary surgery findings in advanced stage ovarian cancer.

  2018cites this paper
• 11 – Epithelial Ovarian Cancer

  2018cites this paper
• A triage strategy in advanced ovarian cancer management based on multiple predictive models for R0 resection: a prospective cohort study

  2018cites this paper
• Comparison of Outcomes Following Complete and Selective Parietal Peritonectomy During Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Advanced Epithelial Ovarian Cancer: A Study by Indian Society of Peritoneal Surface Malignancies (ISPSM)

  2018cites this paper
• Comparison of stage III mucinous and serous ovarian cancer: a case-control study

  2018cites this paper
• Association Between Secondary Peritoneal Hydatidosis and Peritoneal Carcinomatosis from Ovarian Cancer – A Case Report

  2018cites this paper
• Surgery in ovarian cancer – Brazilian Society of Surgical Oncology consensus

  2018cites this paper
• Positive Surgical Margins in the 10 Most Common Solid Cancers

  2018cites this paper
• Predictive significance of preoperative CT findings for suboptimal cytoreduction in advanced ovarian cancer: a meta-analysis

  2018cites this paper
• Examining Survival Outcomes of 852 Women With Advanced Ovarian Cancer: A Multi-institutional Cohort Study

  2018cites this paper
• Diagnosis and Treatment of Ovarian Cancer.

  2018cites this paper
• Management of Peritoneal Metastases- Cytoreductive Surgery, HIPEC and Beyond

  2018influential citation
• Peran Serum IL-6 dan CA-125 Prabedah sebagai Prediktor Resektabilitas Tumor pada Kanker Ovarium Tipe Epitel

  2018cites this paper
• Control de calidad en la cirugía del cáncer de ovario

  2018cites this paper
• Prognostic factors for maximally or optimally cytoreduced stage III nonserous epithelial ovarian carcinoma treated with carboplatin/paclitaxel chemotherapy

  2018cites this paper
• Surgical Management of Recurrent Epithelial Ovarian Cancer

  2018cites this paper
• Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study.

  2018cites this paper
• Thirty-day unplanned hospital readmission in ovarian cancer patients undergoing primary or interval cytoreductive surgery: systematic literature review.

  2018cites this paper
• Meigs to modern times: The evolution of debulking surgery in advanced ovarian cancer.

  2018cites this paper
• Neoadjuvant chemotherapy and the complexity of operative procedure in advanced epithelial ovarian cancer: a retrospective analysis

  2018cites this paper